Nemvaleukin Alfa Plus Pembrolizumab Fast Tracked for Platinum-Resistant Ovarian Cancer
General Gynecologic Cancers News Oncology Ovarian Cancer

Nemvaleukin Alfa Plus Pembrolizumab Fast Tracked for Platinum-Resistant Ovarian Cancer

The Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer. Nemvaleukin alfa is an investigational engineered fusion protein composed of…